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Abstract The signaling pathways leading to extracellular
signal-regulated kinase (ERK) activation in formyl-methionyl-
leucyl-phenylalanine (fMLP)-stimulated rat neutrophils were
examined. fMLP-stimulated ERK activation based on immuno-
blot analysis with antibodies against the phosphorylation form of
ERK was attenuated by the pretreatment of cells with pertussis
toxin but not with a dual cyclo-oxygenase/lipoxygenase inhibitor
BW755C. Exposure of cells to the tyrosine kinase inhibitor
genistein, phosphatidylinositol 3-kinase (PI3K) inhibitors wort-
mannin and LY294002, or protein kinase C (PKC) inhibitors
Go«6976, Go«6983, and GF109203X inhibited fMLP-stimulated
ERK phosphorylation in a concentration-dependent manner. In
addition, both the phospholipase C (PLC) inhibitor U73122 and
the Ca2 chelator BAPTA attenuated ERK activation. These
results indicate that Gi=o protein, tyrosine kinase, PI3K, PKC,
and PLC/Ca2, but not arachidonate metabolites, act upstream
of fMLP-stimulated ERK activation.
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1. Introduction
Neutrophils constitute the ¢rst line of defense against in-
vading microorganisms and they are activated in response to a
variety of soluble and particle stimuli. After activation, neu-
trophils engage in migration, phagocytosis, granule release,
and the production of reactive oxygen species [1]. Although
the signaling pathways responsible for neutrophil activation
have not been fully delineated, a rapid induction of protein
phosphorylation is thought to be crucial to the regulation of
neutrophil e¡ector functions [2,3]. Although the identities of
many of the phosphorylated substrates present in activated
neutrophils remain unknown, it has been demonstrated that
extracellular signal-regulated kinase (ERK), also known as
p44/42 mitogen-activated protein kinase (MAPK), can be
phosphorylated [4]. Several isoforms of ERK have been de-
scribed, and at least two of them, ERK1 (p44 MAPK) and
ERK2 (p42 MAPK), are expressed in neutrophils [4]. ERK1
shares 85% homology with ERK2, and both are activated as a
result of a cascade of di¡erent upstream kinases [5]. ERK has
been proposed to play roles in cell growth and di¡erentiation
in mitotic cells [6]. Studies of ERK in neutrophils appear to
have revealed some non-mitotic signaling functions for these
enzymes, such as adhesion and superoxide anion generation
[7,8]. These results suggest that ERK may be the component
of signal transduction pathways leading to crucial neutrophil
functional responses during in£ammation and infection.
Cell stimulation induces a signaling cascade that leads to
the activation of ERK via phosphorylation on both tyrosine
and threonine residues within the TEY motif [9]. Structural
analysis of ERK indicates that phosphorylation induces a
conformational change that exposes the active site for sub-
strate binding. Phosphorylation of the TEY motif on ERK
is catalyzed by a dual speci¢city kinase termed MAPK kinase
(MEK). MEK is itself activated by the phosphorylation of
serine residues by Raf or MEK kinase (MEKK) [10]. The
bacterial signal peptide formyl-methionyl-leucyl-phenylalanine
(fMLP) and other chemoattractants activate ERK with ki-
netics concordant with the rapid responses of neutrophils
[4]. Although ERK activation of neutrophils by fMLP has
been suggested via the activation of Ras, Raf, and MEK
[11,12], the signaling pathways responsible for fMLP-stimu-
lated ERK activation have not been fully delineated. In this
study, to understand the proximal signaling pathways in-
volved in fMLP-stimulated ERK activation, the e¡ects of
pharmacological inhibitors of several signaling pathways on
the phosphorylation of ERK were examined.
2. Materials and methods
2.1. Neutrophil isolation
Rat blood was collected from the abdominal aorta and the neutro-
phils were puri¢ed by dextran sedimentation, centrifugation through
Ficoll-Hypaque, and the hypotonic lysis of erythrocytes [13]. Puri¢ed
neutrophils containing s 95% viable cells were normally resuspended
in Hanks’ balanced salt solution (HBSS) containing 10 mM HEPES,
pH 7.4, and 4 mM NaHCO3, and kept in an icebath before use.
2.2. Immunoblotting analysis
Cells were preincubated with test drugs at 37‡C for the indicated
time before stimulation with fMLP plus dihydrocytochalasin B (CB).
One minute later, reactions were quenched by the addition of stopping
solution (20% trichloroacetic acid, 1 mM PMSF, 2 mM N-ethylmale-
imide, 10 mM NaF, 2 mM Na3VO4, 2 mM p-nitrophenyl phosphate,
7 Wg/ml of leupeptin and pepstatin). Proteins were electrophoresed on
10% SDS-polyacrylamide gels and then transferred to polyvinylidene
di£uoride membrane. The membranes were blocked with 5% non-fat
dried milk in TBST bu¡er (10 mM Tris-HCl, pH 7.5, 150 mM NaCl
and 0.1% Tween 20) and probed with rabbit polyclonal anti-phospho-
p44/42 MAPK antibodies (1:2500 dilution in TBST bu¡er with 0.1%
non-fat dried milk). To standardize for protein loading in each lane,
blots were stripped by incubating them in Tris bu¡er (62.5 mM Tris-
HCl, pH 6.8, 100 mM 2-mercaptoethanol, 2% SDS) at 50‡C for
30 min, washed extensively, and followed by reprobing with anti-
bodies against ERK1 and ERK2, or pan-ERK (1:1000 to 1:5000
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dilution in TBST bu¡er with 0.1% non-fat dried milk). Detection was
made using enhanced chemiluminescence reagent.
2.3. Materials
All chemicals were purchased from Sigma (USA) except for the
following: dextran T-500 (Pharmacia, Sweden); Hanks’ balanced
salt solution (Gibco, USA); pertussis toxin (Research Biochemicals
International, USA); U73122 and LY294002 (Biomol, USA);
GF109203X, Go«6976, Go«6983, and wortmannin (Calbiochem,
USA); U0126 (Promega, USA); BAPTA-AM (Molecular Probes,
USA); enhanced chemiluminescence reagent (Amersham, UK); poly-
vinylidene di£uoride membrane (Millipore, USA); mouse monoclonal
antibodies to ERK1, ERK2, and pan-ERK (Transduction, USA);
and rabbit polyclonal antibodies to phospho-p44/42 MAPK (New
England, USA). BW755C was provided by Wellcome Research (UK).
3. Results and discussion
3.1. Phosphorylation of ERK via a G protein-dependent and
arachidonate metabolite-independent pathway
ERK-mediated signaling pathways convert extracellular
stimulation into a variety of cellular functions. However, the
signal transduction events upstream to ERK occurring in neu-
trophils in response to fMLP have been incompletely de-
lineated. Based on immunoblot analysis with anti-phospho-
p44/42 MAPK antibodies, we found that exposure of neutro-
phils to fMLP rapidly induced the activation of ERK, recon-
cile the earlier reports [14,15], and these responses were at-
tenuated by 0.3 WM U0126 (Fig. 1) as well as 3 WM PD98059
(data not shown), both selective MEK inhibitors [16,17].
Heterotrimeric G protein-coupled receptors are able to in-
duce a variety of responses including the activation of several
intracellular kinase cascades. Recent data have shown that the
activation of ERK induced by G protein-coupled receptors in
mammalian cells is mediated by tyrosine phosphorylation of
Shc, leading to increased functional association among the
adapter proteins Shc, Grb2, and Sos, and then Ras/ERK ac-
tivation [18]. Preincubation of rat neutrophils with pertussis
toxin (PTX), a potent endotoxin that catalyzes ADP-ribosyl-
ation of Gi=o, greatly inhibited ERK activation by fMLP (Fig.
1), consistent with the previous reports in human neutrophils
[11,14].
fMLP operates via PTX-sensitive G protein-coupled recep-
tors to activate phospholipase A2, which in turn releases
arachidonate (AA) from membrane phospholipids [19]. The
endogenous AA released is subject to conversion to the me-
tabolites of cyclo-oxygenase (COX) and lipoxygenase (LO). A
recent report indicates that AA, acting as a second messenger,
is able to stimulate the phosphorylation and activity of ERK
in a variety of cell types including human neutrophils [20].
The activation of ERK by AA through an LO-dependent
but COX-independent pathway has been reported in vascular
smooth muscle cells [21] and in human neutrophils [22]. The
inability of BW755C, a dual inhibitor of COX and LO [23], to
prevent ERK activation by fMLP in rat neutrophils (Fig. 1)
eliminated this possibility. In addition, the pretreatment of
cells with 30 nM MK886, a leukotriene biosynthesis inhibitor
[24], or 1 WM indomethacin had no e¡ect on the fMLP-in-
duced response (data not shown). Thus, these data indicate
that the activation of ERK by fMLP is not regulated by the
AA metabolites of COX and LO in rat neutrophils.
3.2. Tyrosine kinase acts upstream of ERK phosphorylation
A previous study indicated that G protein-mediated Shc
phosphorylation is sensitive to tyrosine kinase inhibitors
[25]. PTX-sensitive activation of the Src family kinase Lyn
in human neutrophils has been reported. Activation of Lyn
is associated with binding to the Shc adapter protein and
allows the G protein-coupled receptors to modulate the activ-
ity of the Ras/ERK cascade [26]. The treatment of rat
neutrophils with genistein, a general protein tyrosine kinase
inhibitor [27], concentration-dependently reduced the phos-
phorylation of ERK (Fig. 2), suggesting an involvement of
tyrosine kinase in fMLP-stimulated activation. These results
are similar to earlier observations of human neutrophils [4], in
which the e¡ect of genistein was analyzed by immunoblot
with anti-phosphotyrosine antibodies, and on HL60 cells
[28], in which 30 WM genistein inhibited ERK activity.
3.3. Phosphorylation of ERK is dependent on PI3K
The participation of phosphatidylinositol 3-kinase (PI3K)
in ERK cascade activation after the stimulation of G pro-
tein-coupled receptors has been reported in a variety of cell
types [29,30]. Complexes of phosphorylated Lyn and Shc with
PI3K are rapidly formed in fMLP-stimulated neutrophils [26].
Neutrophils contain two classes of PI3K, the classical tyrosine
kinase-regulated PI3KK (p85/p110K) and a novel GLQ-regu-
Fig. 1. E¡ect of PTX, BW755C and U0126 on fMLP-stimulated
ERK phosphorylation. Cells were preincubated at 37‡C with the ve-
hicle, 1 Wg/ml of PTX for 2 h, 30 WM BW755C or 0.3 WM U0126
for 10 min, either before stimulation with 0.1 WM fMLP plus 5 Wg/
ml CB or without stimulation as a control. One minute later, phos-
phorylation of ERK was detected by immunoblot analysis using
anti-phospho-p44/42 MAPK antibodies. The lower blot was gener-
ated by reprobing the blot above with anti-ERK1 and anti-ERK2
(for PTX and BW755C experiments), or anti-pan ERK (for the
U0126 experiment) antibodies as a measure of total ERK. The data
presented are representative of three independent experiments with
similar results.
Fig. 2. Involvement of tyrosine kinase activation in fMLP-stimu-
lated ERK phosphorylation. Cells were pretreated with the vehicle
or indicated concentrations (WM) of genistein for 30 min at 37‡C ei-
ther before stimulation with 0.1 WM fMLP plus 5 Wg/ml CB or
without stimulation as a control. One minute later, phosphorylation
of ERK was detected by immunoblot analysis using anti-phospho-
p44/42 MAPK antibodies. The lower blot was generated by reprob-
ing the blot above with anti-pan ERK antibodies as a measure of
total ERK. The data presented are representative of three independ-
ent experiments with similar results.
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lated PI3KQ (p101/p110Q) [31]. In order to evaluate the role of
PI3K in fMLP-stimulated ERK activation in rat neutrophils,
wortmannin, an irreversible inhibitor of PI3K [32], was used.
Wortmannin concentration-dependently inhibited the activa-
tion of ERK, as demonstrated by immunoblot using anti-
phospho-p44/42 MAPK antibodies (Fig. 3). Wortmannin at
0.3 WM signi¢cantly reduced ERK phosphorylation, with re-
sults similar to previous observations of inhibiting PAF-
stimulated ERK activity in guinea pig neutrophils [33], and
at 10 WM it inhibited the fMLP-induced response to non-de-
tectable levels, suggesting an involvement of PI3K in fMLP-
stimulated activation. However, wortmannin has also been
reported to inhibit phospholipase D and other kinases [34].
Therefore, the involvement of PI3K in fMLP-stimulated ERK
activation was further tested using a speci¢c PI3K inhibitor,
LY294002 [35]. LY294002 also inhibited ERK phosphoryla-
tion in a concentration-dependent manner (Fig. 3). However,
the inhibitory activity of LY294002 was signi¢cantly less po-
tent than that of wortmannin. A similar observation has been
reported in HL60 cells [28]. The inhibition of ERK activation
by wortmannin and LY294002 suggests that PI3K acts as one
component of upstream regulators of fMLP-stimulated ERK
activation.
3.4. PKC acts as a proximal signaling pathway to activate
ERK
Activated protein kinase C (PKC) has been reported to
stimulate ERK, Ras, and Raf in a number of cell types
[36,37]. In addition, PMA stimulates neutrophil ERK activity,
and this e¡ect has been inhibited by PKC inhibitors [22]. In
this study, we used several PKC inhibitors to evaluate the role
of PKC on fMLP-stimulated ERK activation in rat neutro-
phils. Pretreatment of cells with Go«6983, Go«6976, or
GF109203X signi¢cantly attenuated ERK phosphorylation
in a concentration-dependent manner (Fig. 4). These results
support the recent reports that fMLP-stimulated ERK activity
is inhibited by GF109203X and calphostin C in human neu-
trophils and HL60 cells, respectively [12,28]. Since the discov-
ery of PKC, several PKC isoforms have been identi¢ed. Our
previous report demonstrated that rat neutrophils express
PKCK, L, gamma;, N, O, a, W, S/V, and j, although V and j
are barely detected [38]. Our recent study indicated that PKCQ
is not expressed in rat neutrophils (data not shown). The
di¡erent results are due to the anti-PKCQ antibody that we
used in our previous report also cross-reacting with PKCK.
The pivotal role of PKC in cellular signaling instigated the
search for potent and selective PKC inhibitors. Go«6976 pref-
erentially inhibits PKCK, L, and W, Go«6983 inhibits PKCK, L,
Q, N and j, and GF109203X inhibits PKCK, L, N, O, j and W in
in vitro kinase assays [39,40]. Both Go«6983 and GF109203X
inhibited PKC isoforms with speci¢city broader than Go«6976,
however, their e¡ects on the inhibition of ERK activation
were not more pronounced. These results suggest that Ca2-
dependent PKC probably acts as the major PKC isoforms on
Fig. 3. PI3K acts upstream of ERK activation by fMLP. Cells were
pretreated with the vehicle or indicated concentrations (WM) of
wortmannin (upper blot) or LY294002 (middle blot) for 10 min at
37‡C either before stimulation with 0.1 WM fMLP plus 5 Wg/ml CB
or without stimulation as a control. One minute later, phosphoryla-
tion of ERK was detected by immunoblot analysis using anti-phos-
pho-p44/42 MAPK antibodies. Data are representative of three simi-
lar experiments. The blots above were then stripped and reprobed
with anti-pan ERK antibodies as a measure of total ERK. The low-
er blots shown are representative of similar results.
Fig. 4. The role of PKC in fMLP-stimulated ERK phosphorylation.
Cells were pretreated with the vehicle or indicated concentrations
(WM) of Go«6983 (upper blot), Go«6976 (2nd blot), or GF109203X
(3rd blot) for 10 min at 37‡C either before stimulation with 0.1 WM
fMLP plus 5 Wg/ml CB or without stimulation as a control. One
minute later, phosphorylation of ERK was detected by immunoblot
analysis using anti-phospho-p44/42 MAPK antibodies. Data are rep-
resentative of three similar experiments. The blots above were then
stripped and reprobed with anti-pan ERK antibodies as a measure
of total ERK. The lower blots shown are representative of similar
results.
Fig. 5. Elevation of [Ca2]i is necessary for ERK activation by
fMLP. Cells were stimulated with 0.1 WM fMLP plus 5 Wg/ml CB
or its diluent for 1 min. Where indicated, the cells had been pre-
treated at 37‡C with the vehicle or 10 WM U73122 for 10 min or
were loaded with BAPTA by incubation with 10 WM BAPTA-AM
for 1 h. After stimulation, phosphorylation of ERK was detected by
immunoblot analysis using anti-phospho-p44/42 MAPK antibodies.
The lower blot was generated by reprobing the blot above with
anti-ERK1 and anti-ERK2 antibodies as a measure of total ERK.
The data presented are representative of three independent experi-
ments with similar results.
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the regulation of fMLP-stimulated ERK phosphorylation,
whereas the inhibition of novel and atypical PKC isoforms
failed to improve but partially reduced the e⁄cacy. It has
been reported that fMLP induces G-dependent activation of
Ras, Raf, and MEKK in human neutrophils in a PKC-inde-
pendent manner [11,12]. On the other hand, GF109203X and
staurosporine inhibit the activities of ERK and MEK, respec-
tively, in human neutrophils [12,41]. Therefore, PKC may
probably act downstream of Raf/MEKK to regulate the
fMLP-stimulated ERK cascade.
3.5. PLC/Ca2 pathway couples to the activation of ERK
The stimulation of neutrophils by receptor-binding ligands
can activate phospholipase C (PLC) with the formation of
inositol trisphosphate, which increases in [Ca2]i, and diacyl-
glycerol, which activates PKC [42]. We next investigated the
role of PLC/Ca2 on ERK activation. PAF activates ERK
through a Ca2-dependent pathway in guinea pig neutrophils
[33], and fMLP-stimulated ERK activity in HL60 cells was
dependent on PLC [28]. On the contrary, experiments using
electropermeabilized human neutrophils indicated that eleva-
tion of [Ca2]i is not required for activation of MEK by
fMLP [41]. Our results using the PLC inhibitor U73122 [43]
and the intracellular Ca2 chelator BAPTA [44] to prevent the
increase of [Ca2]i showed the attenuation of fMLP-stimu-
lated ERK phosphorylation (Fig. 5) and suggest that fMLP
activates ERK also through a PLC/Ca2-dependent pathway.
In summary, our results demonstrated that fMLP activates
ERK via PTX-sensitive G protein, not through AA metabo-
lites, and is regulated by tyrosine kinase, PI3K, PKC, and
PLC/Ca2 signaling pathways in rat neutrophils.
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